Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy

Authors: Gisèle Compaci, Manuela Rueter, Sébastien Lamy, Lucie Oberic, Christian Recher, Maryse Lapeyre-Mestre, Guy Laurent, Fabien Despas

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Cancer survivorship has emerged as an important aspect of oncology due to the possibility of physical and psychosocial complications. The purpose of this study was to assess the feasibility of the Ambulatory Medical Assistance for After Cancer (AMA-AC) procedure for monitoring lymphoma survivorship during the first year after chemotherapy.

Methods

AMA-AC is based on systematic general practitioner (GP) consultations and telephone interventions conducted by a nurse coordinator (NC) affiliated to the oncology unit, while an oncologist acts only on demand. Patients are regularly monitored for physical, psychological and social events, as well as their health-related quality of life (HRQoL). Inclusion criteria were patients newly diagnosed with non-Hodgkin or Hodgkin lymphomas, who had been treated with anthracycline-based chemotherapy and were in complete remission after treatment.

Results

All 115 patients and 113 collaborating GPs agreed to participate in the study. For patients who achieved one year of disease-free survival (n = 104) their assessments (438 in total) were fully completed. Eleven were excluded from analysis (9 relapses and 2 deaths). The most frequent complications when taking into account all grades were arthralgia (64.3 %) and infections (41.7 %). About one third of patients developed new diseases with cardiovascular complications as the most common. Psychological disorders such as anxiety, depression and post-traumatic stress disorder were diagnosed in 42.6 % of patients. The data collected showed that Hodgkin lymphoma patients, females, and patients with lower HRQoL (mental component) at study entry were at greater risk for developing at least one psychological disorder.

Conclusion

This study showed that AMA-AC is a feasible and efficient procedure for monitoring lymphoma survivorship in terms of GP and patient participation rates and adherence, and provides a high quality of operable data. Hence, the AMA-AC procedure may be transferable into clinical daily practice as an alternative to standard oncologist-based follow-up.
Appendix
Available only for authorised users
Literature
1.
Smith SK, Mayer DK, Zimmerman S, Williams CS, Benecha H, Ganz PA, et al. Quality of life among long-term survivors of non-Hodgkin lymphoma: a follow-up study. J Clin Oncol. 2013;31(2):272–9.CrossRefPubMed
2.
Smith SK, Zimmerman S, Williams CS, Benecha H, Abernethy AP, Mayer DK, et al. Post-traumatic stress symptoms in long-term non-Hodgkin’s lymphoma survivors: does time heal? J Clin Oncol. 2011;29(34):4526–33.CrossRefPubMedPubMedCentral
3.
Oerlemans S, Mols F, Nijziel MR, Zijlstra WP, Coebergh JWW, van de Poll-Franse LV. The course of anxiety and depression for patients with Hodgkin’s lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry. J Cancer Surviv Res Pract. 2014;8(4):555–64.CrossRef
4.
Horsboel TA, Nielsen CV, Nielsen B, Jensen C, Andersen NT, de Thurah A. Type of hematological malignancy is crucial for the return to work prognosis: a register-based cohort study. J Cancer Surviv Res Pract. 2013;7(4):614–23.CrossRef
5.
Jensen RE, Arora NK, Bellizzi KM, Rowland JH, Hamilton AS, Aziz NM, et al. Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma. Cancer. 2013;119(3):672–80.CrossRefPubMed
6.
Maurer MJ, Ghesquières H, Jais J-P, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–73.CrossRefPubMedPubMedCentral
7.
Hiripi E, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S, et al. Survival from common and rare cancers in Germany in the early 21st century. Eur Soc Med Oncol ESMO. 2012;23(2):472–9.CrossRef
8.
9.
Del Giudice ME, Grunfeld E, Harvey BJ, Piliotis E, Verma S. Primary care physicians’ views of routine follow-up care of cancer survivors. J ClinOncol. 2009;27(20):3338–45.CrossRef
10.
11.
McCabe MS, Bhatia S, Oeffinger KC, Reaman GH, Tyne C, Wollins DS, et al. Amercian Society of clinical oncology statement: achieving high-quality cancer survivorship care. J ClinOncol. 2013;31(5):631–40.CrossRef
12.
13.
Cheung WY, Aziz N, Noone A-M, Rowland JH, Potosky AL, Ayanian JZ, et al. Physician preferences and attitudes regarding different models of cancer survivorship care: a comparison of primary care providers and oncologists. J Cancer Surviv Res Pract. 2013;7(3):343–54.CrossRef
14.
Donnelly P, Hiller L, Bathers S, Bowden S, Coleman R. Questioning specialists’ attitudes to breast cancer follow-up in primary care. J Eur Soc Med Oncol ESMO. 2007;18(9):1467–76.CrossRef
15.
Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32(31):3506–12.CrossRefPubMedPubMedCentral
16.
17.
Hendren S, Fiscella K. Patient navigation improves the care experience for patients with newly diagnosed cancer. J Clin Oncol. 2014;32(1):3–4.CrossRefPubMed
18.
Girgis A, Breen S, Stacey F, Lecathelinais C. Impact of two supportive care interventions on anxiety, depression, quality of life, and unmet needs in patients with nonlocalized breast and colorectal cancers. J Clin Oncol. 2009;27(36):6180–90.CrossRefPubMed
19.
DuHamel KN, Mosher CE, Winkel G, Labay LE, Rini C, Meschian YM, et al. Randomized clinical trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic stem-cell transplantation. J Clin Oncol. 2010;28(23):3754–61.CrossRefPubMedPubMedCentral
20.
Compaci G, Ysebaert L, Obéric L, Derumeaux H, Laurent G. Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: the Ambulatory Medical Assistance (AMA) experience. Int J Nurs Stud. 2011;48(8):926–32.CrossRefPubMed
21.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol. 2007;25(5):579–86.CrossRefPubMed
22.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.CrossRefPubMed
23.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
24.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61.CrossRefPubMed
25.
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.CrossRefPubMed
26.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–14.CrossRefPubMed
27.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMed
28.
Razavi N, Delvaux N, Farvacques C, Robaye E. Validation de la version française du HADS dans une population de patients cancéreux hospitalisés. / Validation of the French version of the Hospital Anxiety and Depression Scale (HADS) in a population of hospitalized cancer patients. Rev Psychol Appliquée. 1989;39:295–307.
29.
Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA. Psychometric properties of the PTSD checklist (PCL). Behav Res Ther. 1996;34(8):669–73.CrossRefPubMed
30.
Ventureyra VAG, Yao S-N, Cottraux J, Note I, De Mey-Guillard C. The validation of the Posttraumatic Stress Disorder Checklist Scale in posttraumatic stress disorder and nonclinical subjects. Psychother Psychosom. 2002;71(1):47–53.CrossRefPubMed
31.
Shelby RA, Golden-Kreutz DM, Andersen BL. Mismatch of posttraumatic stress disorder (PTSD) symptoms and DSM-IV symptom clusters in a cancer sample: Exploratory factor analysis of the PTSD Checklist-Civilian Version. J Trauma Stress. 2005;18(4):347–57.CrossRefPubMedPubMedCentral
32.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington D.C.: 1994.
33.
Ware JE, The SCD, MOS. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed
34.
McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;3:247–63.CrossRef
35.
Perneger TV, Leplège A, Etter J-F, Rougemont A. Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults. J Clin Epidemiol. 1995;48(8):1051–60.CrossRefPubMed
36.
Leplège A, Ecosse E, Verdier A, Perneger TV. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol. 1998;51(11):1013–23.CrossRefPubMed
37.
Cohen JW. Statistical Power analysis for the behavioral sciences (2nd edition). Hillsdale: Lawrence Erlbaum Assoicates; 1988.
38.
Recklitis CJ, Sanchez Varela V, Ng A, Mauch P, Bober S. Sexual functioning in long-term survivors of Hodgkin’s lymphoma. Psychooncology. 2010;11:1229–33.CrossRef
39.
Kim B-J, Park H-R, Roh HJ, Jeong D-S, Kim BS, Park K-W, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2010;8:1097–103.CrossRef
40.
Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. J Multinatl Assoc Support Care Cancer. 2014;8:2261–9.CrossRef
41.
Fagerlind H, Kettis Å, Glimelius B, Ring L. Barriers against psychosocial communication: oncologists’ perceptions. J Clin Oncol. 2013;31(30):3815–22.CrossRefPubMed
42.
Forsythe LP, Kent EE, Weaver KE, Buchanan N, Hawkins NA, Rodriguez JL, et al. Receipt of psychosocial care among cancer survivors in the United States. J Clin Oncol. 2013;31(16):1961–9.CrossRefPubMedPubMedCentral
43.
Friedman DR, Coan AD, Smith SK, Herndon JE, Abernethy AP. Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians. Am J Hematol. 2010;85(7):528–32.CrossRefPubMedPubMedCentral
44.
Stanton AL. Psychosocial concerns and interventions for cancer survivors. J Clin Oncol. 2006;24(32):5132–7.CrossRefPubMed
45.
Loge JH, Abrahamsen AF, Ekeberg O, Hannisdal E, Kaasa S. Psychological distress after cancer cure: a survey of 459 Hodgkin’s disease survivors. Br J Cancer. 1997;76(6):791–6.CrossRefPubMedPubMedCentral
46.
Smith SK, Zimmerman S, Williams CS, Preisser JS, Clipp EC. Post-traumatic stress outcomes in non-Hodgkin’s lymphoma survivors. J Clin Oncol. 2008;26(6):934–41.CrossRefPubMedPubMedCentral
47.
Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M. Screening for depression and anxiety in women with breast and gynaecologic cancer: course and prevalence of morbidity over 12 months. Psychooncology. 2013;22(9):2071–8.CrossRefPubMed
48.
Fobair P, Hoppe RT, Bloom J, Cox R, Varghese A, Spiegel D. Psychosocial problems among survivors of Hodgkin’s disease. J Clin Oncol. 1986;4(5):805–14.PubMed
49.
Reeve BB, Potosky AL, Smith AW, Han PK, Hays RD, Davis WW, et al. Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst. 2009;101(12):860–8.CrossRefPubMedPubMedCentral
50.
Kornblith AB, Herndon JE, Zuckerman E, Cella DF, Cherin E, Wolchok S, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin’s disease and acute leukemia survivors. Cancer and Leukemia Group B. J Eur Soc Med Oncol ESMO. 1998;9(3):297–306.CrossRef
51.
Shand LK, Cowlishaw S, Brooker JE, Burney S, Ricciardelli LA. Correlates of post-traumatic stress symptoms and growth in cancer patients: a systematic review and meta-analysis. Psychooncology. 2014. doi: 10.​1002/​pon.​3719.
Metadata
Title
Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy
Authors
Gisèle Compaci
Manuela Rueter
Sébastien Lamy
Lucie Oberic
Christian Recher
Maryse Lapeyre-Mestre
Guy Laurent
Fabien Despas
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1815-7

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome

Technical advance

Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells

Research article

MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability

Research article

Molecular mechanism of anti-cancer activity of phycocyanin in triple-negative breast cancer cells

Research article

G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy

Case report

Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits